2022 annual financial data
CRISPR Therapeutics 2022 Net margin
Direct answer
Net margin was -149,122.71%.
Operating income was -673,161,000 USD and net income was -650,175,000 USD.
Operating cash flow was -495,741,000 USD.
Get free CRISPR Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 436,000 USD
- Operating income
- -673,161,000 USD
- Net income
- -650,175,000 USD
- Operating cash flow
- -495,741,000 USD